The meeting has already been uploaded and can be found here:
GSS is the first presenter. - Positive Cashflow for FY21
- 3Base system able to detect current/future mutants, e.g. Delta, Lambda etc..
- Sample to result instrument in the making - I agree that this will be the game changer here, labs are really busy these day and this is the sort of thing they are looking for.. Although they run the risk of being a little bit too late, as big American companies are already there..
- pending enteric protozoan FDA clearance in the US - big market for that..
- GSS reckon they cover about 10% of Sars Cov PCR test in Australia, which sounds about right.. Come on Australia, support our own!
GSS Price at posting:
$1.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)